19540 studies found for:    T
Show Display Options
Rank Status Study
1 Completed Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism
Conditions: Quality of Life;   Depression
Intervention: Drug: Triiodothyronine
2 Terminated A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
Condition: Alzheimers Disease
Intervention: Radiation: [F18] T808
3 Recruiting CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Conditions: Peripheral T-cell Lymphoma NOS;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic Gamma/ Delta T-cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Gemcitabine;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: methylprednisolone;   Drug: Cisplatin
4 Completed Assessment of the Clinical Efficacy and Acceptability of Think Positive (T+) in Diabetes Management
Condition: Diabetes (Insulin-requiring, Type 1 or Type 2)
Intervention: Device: Mobile phone telehealth application: Think Positive (T+)
5 Completed
Has Results
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™
Conditions: Diphtheria;   Tetanus;   Pertussis;   Hepatitis B;   Poliomyelitis;   Haemophilus Influenzae Type B Infection
Interventions: Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 1);   Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 2);   Biological: DTaP-IPV-Hep B-PRP~T vaccine (Batch 3);   Biological: Infanrix Hexa™
6 Completed
Has Results
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infants
Conditions: Diphtheria;   Tetanus;   Whooping Cough;   Hepatitis B;   Poliomyelitis
Interventions: Biological: DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide;   Biological: DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide;   Biological: DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine
7 Recruiting Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
8 Completed
Has Results
Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?
Condition: Low T3 Syndrome
Interventions: Drug: Oral T3 Low dose;   Drug: Placebo;   Drug: Oral T3 high dose
9 Recruiting Central Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis
10 Recruiting Escalating Doses of Torisel in Combination With Three Chemotherapies Regimens: R-CHOP, R-FC or R-DHA for Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL).
Condition: Mantle Cell Lymphoma Refractory
Interventions: Drug: Torisel and R-CHOP;   Drug: Torisel and R-FC;   Drug: Torisel and R-DHA
11 Recruiting Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: T2;   Drug: Azathioprine
12 Recruiting Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Phase Chronic Myelogenous Leukemia;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Interventions: Biological: WT1-sensitized T cells;   Biological: aldesleukin;   Other: laboratory biomarker analysis
13 Not yet recruiting T2 Mapping of the Heart in Acute Myocardial Infarction Population for the Prediction of Short Term Major Adverse Cardiovascular Events
Condition: Myocardial Infarction, Acute
Intervention:
14 Completed CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells
Condition: Liver Metastases
Intervention: Biological: anti-CEA 2nd generation designer T cells
15 Not yet recruiting Phase I Trial: T4 Immunotherapy of Head and Neck Cancer
Condition: Head and Neck Cancer
Intervention: Other: Intra-tumoral T4 immunotherapy
16 Recruiting Home-based Program "T&E" for Fall Prevention and QoL in Elderly: a Randomised Control Pilot-study
Condition: Accidental Falls
Interventions: Other: T&E;   Other: OTAGO
17 Active, not recruiting A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
Conditions: Adult T-cell Leukemia-Lymphoma;   Peripheral T-cell Lymphoma
Intervention: Drug: Lenalidomide
18 Completed Liothyronine (T3) for Bipolar Depression
Conditions: Depression;   Bipolar Disorder
Interventions: Drug: Liothyronine (T3);   Drug: placebo
19 Recruiting A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.
Condition: Breast Cancer
Interventions: Drug: T-DM1;   Drug: Trastuzumab
20 Completed
Has Results
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
Condition: Metastatic Breast Cancer
Interventions: Biological: pertuzumab;   Biological: Trastuzumab emtansine [Kadcyla]

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years